Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$61.6 million.

  • SAB Biotherapeutics' Gains from Investment Securities fell 208944.44% to -$61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.8 million, marking a year-over-year decrease of 235420.13%. This contributed to the annual value of $3.0 million for FY2024, which is 19399.64% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Gains from Investment Securities stood at -$61.6 million for Q3 2025, which was down 208944.44% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Gains from Investment Securities peaked at $9.6 million during Q1 2023, and registered a low of -$61.6 million during Q3 2025.
  • Its 5-year average for Gains from Investment Securities is -$1.4 million, with a median of $2.3 million in 2024.
  • As far as peak fluctuations go, SAB Biotherapeutics' Gains from Investment Securities surged by 1302042.04% in 2023, and later tumbled by 208944.44% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Gains from Investment Securities (Quarter) stood at $3.9 million in 2021, then tumbled by 100.94% to -$36586.0 in 2022, then soared by 13020.42% to $4.7 million in 2023, then crashed by 51.21% to $2.3 million in 2024, then tumbled by 2770.83% to -$61.6 million in 2025.
  • Its Gains from Investment Securities was -$61.6 million in Q3 2025, compared to $2.9 million in Q2 2025 and -$5.0 million in Q1 2025.